Liquid Biopsy: A Better Tool For Screening Breast Cancer Pat
A recent study revealed that liquid biopsy can help to identify breast cancer patients with a poor prognosis earlier and more accurately. The study aimed to investigate the prognostic potential of circulating cell-free DNA (cfDConc) and cfDI in Breast Cancer cases with a non-metastatic disease. Researchers selected 204 BC cases with non-metastatic disease and isolated cfDNA from the serum collected at the time of diagnosis before any treatment was given which was then measured with a fluorometer and electrophoresis and analyzed with 25 years of survival data. Results showed that high cfDConc was not an independent prognostic factor while high cfDI was found to be an independent prognostic factor. These findings suggest that together with traditional prognostic factors, measuring the integrity of cfDNA can in the future help to identify breast cancer patients with a poor prognosis earlier and more accurately than before. This would allow patients requiring more intensive care to be placed under intensified care and monitoring earlier.

If you find this research insightful, please like, comment and share.

For more details, please read:
https://www.mdpi.com/2072-6694/13/18/4679
3 shares
Like
Comment
Share